3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gastrointestinal
1
Conditions
Esophageal Neoplasms
2
Barrett Esophagus
2
Zollinger-Ellison Syndrome
1
Vomiting
1
Stomach Ulcer
1
Precancerous Conditions
1
Neoplasms
1
Nausea
1
Lymphoma
1
Head and Neck Neoplasms
1
Esophagitis, Peptic
1
Breast Neoplasms
1
Interventions
Whole-Body Irradiation
4
Sulindac
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
fludarabine phosphate
3
Selenium
3
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
3
Cetuximab
3
Biopsy
3
Tacrolimus
2
Sirolimus
2
Radiotherapy, Intensity-Modulated
2
Polymerase Chain Reaction
2
Mycophenolic Acid
2
Melphalan
2
Gene Expression Profiling
2
Etoposide
2
Darbepoetin alfa
2
Cyclosporine
2
Cyclophosphamide
2
Cisplatin
2
Busulfan
2
Aspirin
2
Aminolevulinic Acid
2
Albumin-Bound Paclitaxel
2
vandetanib
1
ruxolitinib
1
polyphenon E
1
perillyl alcohol
1
peginterferon alfa-2b
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Precancerous Conditions
×
Esomeprazole
×
Clear all
NCT00357682
2025-05-01
AspECT
University of Oxford
Phase 3
Completed
2,557 enrolled
17 charts